SironaDx
SironaDx
  • Home
  • Platforms
    • Imaging Mass Cytometry
    • CyTOF Mass Cytometry
    • Next Gen. Sequencing
    • Capillary Electophoresis
    • Quantitative RT- PCR
    • NanoString nCounter
  • Services
    • Services overview
    • IMC/Multiplexed IHC
    • CyTOF Mass Cytometry
    • Human Immune Monitoring
    • Targeted Seq. Panels
    • I-O Expression Assay
    • Oncomine Focus
    • Cancer HSM Panel
    • Disease Sp. Cancer Panels
  • About Us
  • News & Events
  • Contact Us
  • COVID-19 Testing
  • More
    • Home
    • Platforms
      • Imaging Mass Cytometry
      • CyTOF Mass Cytometry
      • Next Gen. Sequencing
      • Capillary Electophoresis
      • Quantitative RT- PCR
      • NanoString nCounter
    • Services
      • Services overview
      • IMC/Multiplexed IHC
      • CyTOF Mass Cytometry
      • Human Immune Monitoring
      • Targeted Seq. Panels
      • I-O Expression Assay
      • Oncomine Focus
      • Cancer HSM Panel
      • Disease Sp. Cancer Panels
    • About Us
    • News & Events
    • Contact Us
    • COVID-19 Testing
  • Home
  • Platforms
  • Services
  • About Us
  • News & Events
  • Contact Us
  • COVID-19 Testing

News: April 2022

Sirona Dx Announces Partnership with Scailyte for AI driven end-point specific single cell analysis

April 11, 2022 11:00 AM Eastern Daylight Time

Sirona Dx Announces partnership with Scailyte for AI driven end-point specific single cell analysis

Sirona Dx and Scailyte announce a strategic partnership to accelerate the development of Advanced Therapies. The companies will create a powerful biomarker discovery engine, leveraging Sirona Dx technical and laboratory workflow solutions in combination with Scailyte’s AI-driven data analytics platform ScaiVision™ to serve Biopharma and Biotech. 

Read the joint press release in full

News: March 2022

Ultivue Announces Co-Marketing Agreement with Sirona Dx for Multiplexed Tissue Biomarker Solutions

March 15, 2022 11:00 AM Eastern Daylight Time

Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine


CAMBRIDGE, Mass. & PORTLAND, Ore.--(BUSINESS WIRE)--Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to accelerate the pace of immunotherapy and targeted therapy development, announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and biopharma.


Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. “Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities offered by Sirona Dx. We believe this joint offering will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.” said Mark Rees, Ph.D. Vice President Corporate Development at Ultivue.


Sirona Dx are original pioneers of spatial biology, having launched ultra-high parameter, multiplexed imaging services to Biopharma in 2018. Their technology agnostic, full service, spatial biology suite, contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.  “We are delighted to announce this partnership with Ultivue” said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx. “Since 2018, clients have relied on our leading expertise to develop and implement customized, high performance multiplexed imaging panels of up to 40 markers. Having cast a wide net to identify the most informative tissue biomarker signatures, we can now harness Ultivue’s powerful InSituPlex® technology to rapidly develop, robustly validated mid-plex panels of up to 12 markers enabling our clients to accelerate their drug development programs with transformative biomarker capabilities.

Read the joint press release in full

News: January 2022

Sirona Dx recognized as a Top 10 CRO of 2021 by Medhealth Outlook

Sirona Dx embrace innovative, leading-edge technologies at an early stage and earn recognition as a Top 10 CRO of 2021 by Medhealth Outlook. State of the art high parameter, single cell proteomics services enable ultra-deep immune profiling. Multi-platform spatial biology solutions including Imaging Mass Cytometry and CODEX reveal the complex interplay between the immune system and the tumor microenvironment. 

Read the Full ARTICLE

News: May 2021

Sirona Dx presents at Fluidigm Virtual Mass Cytometry Investor Day

Dr. Nasry Yassa, CEO and Andrew Brown, Chief Commercial Officer, discuss the use of Fluidigm Mass Cytometry technology within their specialty contract research organization. They have created a specialized CRO business that partners with biopharma to accelerate drug development work, with a focus on introducing novel technologies into early clinical stage development. At this event they focus on the adoption of CyTOF and Imaging Mass Cytometry enabling high parameter single cell proteomics readouts to accelerate therapeutic development for their biopharma clients.

Listen to webcast

News: February 2021

Sirona Dx Launches Rapid Saliva Based PCR COVID-19 Testing Service Utilizing Advanced Microfluidics

We have implemented advanced microfluidics technology to enable rapid, accurate, lower cost  

COVID-19 testing on easy to collect saliva samples.   

The Advanta™ SARS-CoV-2 RT-PCR assay was developed by Fluidigm and is supported by an EUA. The assay is a reverse transcription and real-time polymerase chain reaction (RT-PCR) test that leverages Fluidigm microfluidics technology with the Biomark HD platform.

Test results are available within 24h after arrival at our Portland, OR based clinical laboratory. 

Email us for More Information

News: December 2020

AKOYA Customer Spotlight: Supporting Drug Discovery & Development with CODEX

Sirona Dx is a Portland, Oregon-based technical contract research organization (CRO), which provides high-complexity genomics and proteomics services to pharmaceutical and biotech companies to support drug discovery and development in immuno-oncology. Sirona Dx recently brought the CODEX platform on board to support discovery research with single-cell, spatially resolved multiplex imaging.

To learn how the CRO is accelerating drug discovery and development, and how CODEX will help, we spoke to Andrew Brown, PhD, Chief Commercial Officer at Sirona Dx. 

Read the full artcle

News: October 2020

Sirona Dx Recognized as a Top 10 Service Provider for Drug Discovery and Development by Pharma Tech

Read the full artcle

News: November 2018

Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development

Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research


SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov.  01, 2018   (GLOBE NEWSWIRE) -- Sirona Dx, a leader in high-complexity genomics  and proteomics services, today announced the introduction of Imaging  Mass Cytometry™ services on the Fluidigm Hyperion™ Imaging System to  advance biomarker discovery and therapeutic development.
 

 Sirona Dx is a specialized contract research organization (CRO) that  provides high-quality clinical research services to pharmaceutical and  clinical research clients and focuses on offering early access to  advanced technologies.


With a goal of providing innovative approaches to expand drug  discovery pipelines and bring more effective therapies to market, Sirona  Dx decided to add multiplex tissue imaging to its growing technology  portfolio. Noticing impressive Imaging Mass Cytometry results from top  pharmaceutical companies and leading academic medical centers, Sirona Dx  engaged Akil Merchant, M.D., Assistant Professor at the University of Southern California Keck School of Medicine, as a Scientific Advisor to assess its full potential.


“After a comprehensive evaluation of different tissue imaging  technologies, Imaging Mass Cytometry was the clear choice. Imaging Mass  Cytometry will enable our clients to resolve complex cellular networks  and signaling pathways within tissue microenvironments with  unprecedented definition,” said Nasry Yassa, Ph.D., Chief Executive  Officer of Sirona Dx. “The early response from our pharma partners has  been extremely positive. Our clients are expressing significant interest  in using Imaging Mass Cytometry to advance their research goals and are  pleased to access this new technology through an experienced CRO.  Sirona Dx has exciting projects underway and additional requests coming  in from top pharmaceutical companies.”


Developed for research use, Imaging Mass Cytometry enables  simultaneous imaging of up to 37 protein markers from a single scan of  formalin-fixed, paraffin-embedded (FFPE) or fresh tissue sections at  subcellular resolution. Using proven CyTOF® technology, Imaging Mass  Cytometry surpasses the inherent limitations of fluorescence detection  by using high-purity metal tags that are separated by mass instead of by  wavelength. With an established global footprint and 18 scientific  publications to date, Imaging Mass Cytometry is rapidly setting a new  standard for highly multiplexed tissue imaging.


“By preserving tissue architecture and cellular morphology  information, Imaging Mass Cytometry is ideal for understanding complex  tissue microenvironments. It is especially useful for monitoring changes  in the immune system in a variety of disease states such as cancer or  auto-immunity,” said Dr. Merchant. “With easily customizable panel  designs using available pre-conjugated antibodies or metal conjugation  kits, Imaging Mass Cytometry is a valuable tool for translational and  clinical research across a range of disease areas.”


“Sirona Dx is our first Imaging Mass Cytometry CRO partner in the United States,” said Chris Linthwaite, President and CEO of Fluidigm.  “Expanding market accessibility is a top priority for unlocking the  full potential of Imaging Mass Cytometry. CRO partners play a critical  role in providing valuable expertise, accelerating new health insights.”     

News: October 2018

Sirona Dx Launches Novel Urine-Based Bladder Cancer Assay with PD-L1 Quantification Based on IncellDx's Single Cell Immuno-Oncology/PD-L1 Technology

PORTLAND, Ore., Oct. 30, 2018  /PRNewswire/ -- Sirona Dx, a leader in high complexity genomics and  proteomics services, announced today the launch of Oncocyst PD-L1, an  assay using IncellDx technology that detects and quantifies abnormal  bladder cells and immune cells from urine cytology specimens that  express the immune-oncology marker PD-L1 using multi-parameter flow  cytometry and bioinformatics. The algorithm also uses aneuploidy/DNA  content in cells from the bladder, markers often detected by  fluorescence in situ hybridization (FISH) and read using microscopy. The  new high throughput assay is non-subjective and can be performed in  less than 3 hours.

"The ability to batch large numbers of samples to determine the PD-L1  and DNA content status on abnormal urine cytology specimens represents a  major advantage over technologies that require subjective microscopic  assessment and dark rooms to read FISH," reports Dr. Nasry Yassa,  CEO, Sirona Dx. "We are committed to additional assay development  projects with InCellDx to leverage their innovative technology platform  that enables simultaneous cell classification and single cell analysis  of proteomic and genomic biomarkers."

"We are delighted to announce a partnership with Sirona Dx for our  novel platform of single cell proteomic and genomic assays using flow  cytometry and CTC platforms. With simultaneous 30+ marker capabilities  and DNA content on individual cells, we are driving personalized  medicine to the cellular level addressing the profound tumor  heterogeneity in cancer," added Bruce K. Patterson MD, CEO of IncellDx, Inc.

The two companies look forward to presenting the Oncocyst PD-L1 study data at the IncellDx Corporate Symposia, Wednesday, October 31st, at the Association of Molecular Pathology Meeting in San Antonio TX. 

News: July 2017

Fluidigm Introduces Immuno-Oncology Gene Expression Assay for Translational and Clinical Research

Advanta Immuno-Oncology Gene Expression Assay enables efficient  screening of 170 highly informative genes involved in human checkpoint  therapeutic response



SOUTH SAN FRANCISCO, Calif., July 18, 2017 (GLOBE NEWSWIRE) --  Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the  Advanta™ Immuno-Oncology Gene Expression Assay, an optimized qPCR assay  that enables efficient interrogation of tumor immunobiology using proven  Fluidigm® microfluidic technology. Designed for use with the Biomark™  HD system, the Advanta Immuno-Oncology Gene Expression Assay sensitively  detects 170 gene expression markers involved in checkpoint therapeutic  response from FFPE and fresh frozen tumor samples. With the capability  to analyze biomarkers across defined T cell subsets, immune regulation,  immune cell fate, cytokines, chemokines and more, this assay can enable  translational researchers to accelerate the development of checkpoint  immunotherapies and to identify predictive biomarker signatures for  therapeutic response.


Tumor gene expression profiling has proven effective in measuring  immune response during cancer progression and therapeutic response.  Previous approaches using large preconfigured panels containing hundreds  of genes or transcriptome analysis, however, are both costly and  time-consuming. Large preconfigured panels can also be difficult to  customize for specific experimental needs. The Advanta Immuno-Oncology  Gene Expression Assay was developed in collaboration with leading  researchers from academia and biopharma to provide the right balance of  biomarker breadth, assay flexibility and workflow efficiency.


"Sirona Dx specializes in tumor expression profiling of challenging  FFPE samples, and we welcomed the opportunity to partner with Fluidigm  to offer the Advanta Immuno-Oncology Gene Expression Assay," said Nasry  Yassa, CEO of Sirona Dx. "Our pharma clients are universally impressed  with the extremely low input requirements and reduced cost compared to  other approaches and are now able to screen more of their precious  samples."


The Advanta Immuno-Oncology Gene Expression Assay is available as a  two-panel set. The first panel includes 91 key markers of tumor immune  response that were previously shown in a multicenter international  clinical trial to inform tumor progression and checkpoint therapeutic  response. The second panel includes 74 additional highly informative  immuno-oncology markers and 17 open assay inlets for additional  customization. Both panels contain the same five reference genes and can  be purchased and used together or separately.


Combined with Fluidigm microfluidics technology, this Advanta assay  uniquely offers significant workflow efficiencies over traditional gene  expression profiling methods. Each reaction is miniaturized to nanoliter  volume and controlled using precise automation to empower accurate and  cost-effective qPCR testing across a large dynamic range. Since assay  introduction into the microfluidics circuit is under user control,  researchers have the flexibility to add or exchange gene assays within  the panel to achieve experimental goals.


"Immunotherapeutic approaches that harness the body's own immune  system to fight cancer provide great promise to change how cancer is  treated and ultimately cured," said Chris Linthwaite, President and CEO  of Fluidigm. "We are excited to announce the Advanta Immuno-Oncology  Gene Expression Assay as an expansion of our growing portfolio of  workflow solutions for the Biomark HD system to empower this great work.  With the launch of this new assay, we are pleased to bring high-value  innovation to the cancer research community to help advance the future  of cancer care."

News: November 2016

Sirona Dx Expands to include Oncomine Focus Assay

VANCOUVER, Wash. - (Nov. 10, 2016) - Sirona Dx, a  leader in high complexity genomics and proteomics services, today  announced it has adopted Thermo Fisher Scientific's Oncomine Focus Assay  to run on the Ion PGM System and expand its drug development and next  generation sequencing (NGS) services offered to pharmaceutical and  clinical research clients.

Sirona Dx recognizes that pharmaceutical companies require access to  genomic expertise as well as multiple platforms and technologies to  support oncology clinical research studies. After its comprehensive  evaluation and validation, Sirona Dx chose to complement its current  service offerings with the Oncomine Focus Assay, which includes 52 solid  tumor genes, many associated with current oncology therapies and  published evidence.


"We are in a revolutionary time in the world of cancer research. The  ability to understand the specific genomic makeup of a tumor and have  that information drive drug development and eventually treatment is  empowering," said Nasry Yassa, Ph.D., Chief Executive Officer of Sirona  Dx. "The Oncomine Focus Assay represents the best of what is available  in terms of content and technology."

The assay's content is driven by the Oncomine Knowledgebase, the  world's largest curated compendium of cancer genomic information and  confirmed with industry-leading pharmaceutical companies, to help enable  a more unified approach to companion diagnostic and drug development.  It is powered by proven Ion AmpliSeq technology to enable detection of  single nucleotide somatic changes, inversions, insertions and deletions,  as well as gene fusions and copy number variations using as little as  10ng of formalin-fixed paraffin-embedded (FFPE) DNA and RNA in a single  workflow.

"We differentiate ourselves by securing early access to advanced  technologies that align with pharma requirements in support of drug  development programs," said Charles J. Sailey, MD, MS, FCAP, FASCP,  Chief Medical Officer of Sirona Dx. "We are very encouraged by the  ability of the Oncomine Focus Assay to enable routine analysis of FFPE  samples. To further accelerate drug development programs, we're  investigating Ion Torrent solutions for liquid biopsies and circulating  tumor cells with plans to offer additional services in the future."


"Pharmaceutical companies are in the midst of a paradigm shift in  their drug development strategy, which is leading to a pronounced need  for targeted NGS tools that enable precision and efficiency," said  Joydeep Goswami, president of clinical next generation sequencing at  Thermo Fisher Scientific. "We are proud that Sirona Dx has joined the  growing list of partners who have adopted our Oncomine technology in an  effort to help the pharma industry develop new therapeutics."

About Sirona Dx

Sirona Dx is a CLIA accredited technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between life science tools developers and translational clinical research, our laboratory offers specialized high complexity single cell proteomics and genomics services to support drug discovery and development programs.  

Copyright © 2019 SironaDx - All Rights Reserved.

Powered by GoDaddy